UK ag-biotech spinout Resurrect Bio has closed its Series A funding round at $10.3 million, oversubscribed from an earlier $8.1 million first close, in a move that underscores rising investor interest in gene-edited approaches to crop protection.
The round was led by Corteva through its Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S, SynBioVen and AgFunder. The final close brings the company’s total funding to approximately $12.4 million since its 2023 seed round.
The raise follows closely on the heels of a joint development agreement with Corteva, announced in March, focused on developing disease resistance traits in corn – highlighting growing strategic alignment between startups and major seed companies.
Building on a new approach to plant immunity
Resurrect Bio’s technology is based on a concept it first outlined to AgTechNavigator earlier this year: using AI-driven gene editing to “resurrect” dormant disease-resistance mechanisms already present in crop genomes.
Rather than introducing foreign genes or relying solely on agrochemicals, the company aims to unlock natural plant defenses that have been lost or suppressed through domestication – a strategy designed to deliver durable resistance while reducing reliance on pesticides.
The newly raised capital will be used to scale that approach across three core platforms: FloraFold® AI discovery engine, predicting plant–pathogen protein interactions; the high-throughput validation platform, testing those predictions at scale; and the resurrection platform, reactivating cryptic resistance traits in elite germplasm.
Together, these systems are intended to dramatically shorten the timeline from discovery to deployment – an ongoing bottleneck in crop improvement.
From discovery to commercial pipelines
With fresh capital in place, Resurrect Bio is now shifting focus from proof-of-concept to commercial integration with seed companies and breeders.
The company said it is actively seeking further joint development agreements to embed its disease-resistance traits into commercial breeding pipelines.
“We’re building a scalable, AI-driven platform for resurrecting disease resistance in the world’s most important crops,” said CEO Dr Cian Duggan, adding that the raise reflects “growing conviction” in the company’s approach.
For seed companies, the appeal is clear: faster access to durable resistance traits at a time when pathogens are evolving rapidly and chemical solutions face increasing regulatory and resistance pressures.
Rising pressure to move beyond chemicals
The funding comes amid broader structural shifts in crop protection.
Crop disease remains a major and costly challenge globally, yet traditional solutions – particularly chemical pesticides – are coming under increasing scrutiny from regulators and society. At the same time, resistance development continues to erode their long-term effectiveness.
Resurrect Bio’s gene-editing approach offers a potential alternative: embedding resistance directly within the crop, reducing both input costs and environmental impact.
“Crop disease remains a major and often overlooked challenge,” said Elizabeth Klein-Edmonds, investment director at Calculus Capital. “Resurrect Bio’s platform offers a promising solution by reducing dependence on chemicals and boosting yields.”
Strategic backing from major industry players
The participation of Corteva in both funding and development agreements is particularly notable.
It signals that major agribusiness players are not only monitoring but actively investing in genomic and AI-driven approaches to crop protection. For start-ups, this kind of backing can accelerate commercialisation and provide a route to market through established breeding and distribution networks.
The oversubscription of the round also reflects a broader trend: increasing investor appetite for platform technologies that combine AI, biology and gene editing to tackle systemic challenges in agriculture.
Positioning for the next phase of crop protection
Resurrect Bio now faces the next challenge: proving that its approach can deliver consistent, scalable performance across crops and geographies.
If successful, its platform could reshape how disease resistance is developed and deployed – moving the industry away from reactive chemical control towards built-in genetic immunity.
For now, the company’s progress represents a convergence of several major trends: AI-driven discovery; gene editing and precision breeding; and the search for sustainable alternatives to chemical inputs.
With a strengthened balance sheet and growing industry partnerships, Resurrect Bio is positioning itself at the forefront of that shift.
